Business
Adia Nutrition Inc. Delivers Explosive Third Quarter Growth: Revenue Surges Over 100% from Prior Quarter, with Remarkable Profit Margin Exceeding 20%
Winter Park, Florida--(Newsfile Corp. - October 8, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a trailblazer in umbilical cord stem cells and exosome sales and therapies, today announced phenomenal preliminary financial results for the third quarter ended September 30, 2025. The company achieved a monumental revenue increase of more than 100% compared to the second quarter, while posting an extraordinary profit margin exceeding 20% for the quarter. This blockbuster performance cements Adia...
About this update from Adia Nutrition, Inc.
[{"type":"text","content":"Winter Park, Florida--(Newsfile Corp. - October 8, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a trailblazer in umbilical cord stem cells and exosome sales and therapies, today announced phenomenal preliminary financial results for the third quarter ended September 30, 2025. The company achieved a monumental revenue increase of more than 100% compared to the second quarter, while posting an extraordinary profit margin exceeding 20% for the quarter. This blockbuster performance cements Adia Nutrition's leadership in the thriving regenerative medicine industry, driven by soaring demand for its innovative, science-driven stem cell and exosome therapies.","length":661,"tagName":"p"},{"type":"text","content":""This third quarter marks a historic leap forward for Adia Nutrition," said CEO Larry Powalisz. "Doubling our revenue in a single quarter while achieving such a robust profit margin is a powerful reflection of our team's dedication, our cutting-edge therapeutic portfolio, and the trust of our rapidly expanding customer base. We're not just growing, we're redefining what's possible in the regenerative medicine space."","length":456,"tagName":"p"},{"type":"text","content":"Key highlights from the preliminary third quarter results include:","length":66,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue Surge: Revenue grew by over 100% from the second quarter, fueled by skyrocketing sales of umbilical cord stem cells and exosomes across clinical partnerships, direct-to-consumer channels, and national market expansion.","length":226,"tagName":"p"}]},{"val":[{"type":"text","content":"Profit Triumph: A profit margin exceeding 20%, showcasing operational efficiency, strategic investments, and the strength of high-margin therapeutic offerings resonating with patients and healthcare providers.","length":209,"tagName":"p"}]},{"val":[{"type":"text","content":"Unstoppable Momentum: These results build on Adia Nutrition's year-to-date success, positioning the company for record-breaking annual growth and enhanced shareholder value.","length":177,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":612,"olType":false},{"type":"text","content":"The full third quarter financial report, including reviewed statements and detailed metrics, will be released and posted ...